Pharmaceutical

Resolution scores $83m to develop macrophage cell therapies

Resolution plans to use Series B investment to advance the development of its macrophage therapies in inflammatory and fibrotic indications.

Oct 4, 2024 - 04:00
Resolution scores $83m to develop macrophage cell therapies
Resolution plans to use Series B investment to advance the development of its macrophage therapies in inflammatory and fibrotic indications.
Read the original article

Tags:

Previous Article

A rational design approach to RNA-targeting to target large-scale screening

Next Article

Chronic diseases “as urgent as climate change,” says Novo Nordisk CSO

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AZ to terminate once-daily cotadutide program to focus on weekly GLP-1RA co-agonist

AZ to terminate once-daily cotadutide program to focus ...

Apr 22, 2023

Islet transplantation for type 1 diabetes: Do regulators have it right?

Islet transplantation for type 1 diabetes: Do regulator...

Oct 9, 2023

Alvotech’s AVT05 in phase III rheumatoid arthritis study, as the sole candidate

Alvotech’s AVT05 in phase III rheumatoid arthritis stud...

Sep 23, 2023